Obermatt
See Similar Stocks →

Revolution Medicines

NSQ:RVMD · US76155X1000
BiotechnologySmall

360° View

32
Price/Sales35
Price/Earnings90
Price/Book1
Dividend Yield—
Revenue Growth100
Profit Growth1
Capital Growth29
TSR 52w86
Leverage34
Liquidity34
Refinancing61
Combined22
Analyst Opinions51
Pro Holdings89
Opinion Changes66
Market Pulse71

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2014
Employees910
Websiterevmed.com
ISINUS76155X1000
Last UpdateApr 2, 2026
Index & Theme
OncologyHealth CareLife ScienceMedical

Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities, built upon deep chemical biology an…

Analysis

Revolution Medicines's 360° View rank of 32 places it below its peer average — better than 32% of its true peers.

It's growing slowly (28) and reasonably valued (59). On safety it is carrying more balance-sheet risk (27), and the market shows strongly positive sentiment (87). Taken together, its Combined rank of 22 reads as among the weakest overall.

360° rank · history

1007550250
32
2026

All-time high

32

Jun 2026

All-time low

17

Mar 2026

Average rank

25

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
35
—
—
—
Price/Earnings
90
—
—
—
Price/Book
1
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
59
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Revolution Medicines with its peers
Black Diamond Therapeutics
NSQ:BDTX
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BridgeBio Oncology Therapeutics
NMQ:BBOT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BIOAGE Labs
NSQ:BIOA
23
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Immuneering
NMQ:IMRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →